Prospective, single-centre study investigating efficacy of immunotherapy (Ipilimumab or Interleukin-2) after regional chemotherapy in patients with in-transit melanoma

Trial Profile

Prospective, single-centre study investigating efficacy of immunotherapy (Ipilimumab or Interleukin-2) after regional chemotherapy in patients with in-transit melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Interleukin-2 (Primary) ; Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top